Malte Braitmaier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Malte Braitmaier has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Vanessa Didelez
Department of Biometry and Data Management Leibniz Institute for Prevention Research and Epidemiology ‐ BIPS Bremen Germany
6 shared publications Ulrike Haug
Department of Clinical Epidemiology, Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany; Faculty of Human and Health Sciences, University of Bremen, Germany
4 shared publications- Ulrike Haug
Department of Clinical Epidemiology, Leibniz Institute for Prevention Research and Epidemiology–BIPS, Bremen, Germany
4 shared publications - Sarina Schwarz
Department of Clinical Epidemiology, Leibniz Institute for Prevention Research and Epidemiology – BIPS , Bremen
3 shared publications - Bianca Kollhorst
Department of Biometry and Data Management, Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany
2 shared publications - Oliver Riedel
Department of Clinical Epidemiology, Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany
2 shared publications
Latest Publications
- 1 April 2025
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 195 (2) , 300-306
Misleading and avoidable: design-induced biases in observational studies evaluating cancer screening—the example of site-specific effectiveness of screening colonoscopy
Observational studies evaluating the effectiveness of cancer screening are often biased due to nonalignment at time zero, which can be avoided by target trial emulation (TTE). We aimed to illustrate this by evaluating site-specific effectiveness of screening colonoscopy regarding colorectal cancer (CRC) incidence. Based on a German health care database, we assessed the effect of screening colonoscopy vs no screening colonoscopy in preventing CRC in the distal and the proximal colon over 12 years of follow-up in 55-69-year-old persons. We compared four different study designs: cohort and case–control study, each with/without alignment at time zero. In both analyses with time zero-alignment, screening colonoscopy showed a rather similar effectiveness in reducing the incidence of distal and proximal CRC (cohort analysis: 32% (95% CI, 27%-37%) vs 28% (20%-35%); case–control analysis: 27% vs 33%). Both analyses without alignment suggested a difference by site: Incidence reduction regarding distal and proximal CRC, respectively, was 65% (61%-68%) vs 37% (31%-43%) in the cohort analysis and 77% (67%-84%) vs 46% (25%-61%) in the case–control analysis. Violations of basic design principles can substantially bias the results of observational studies. In our example, it falsely suggested a much stronger preventive effect of colonoscopy in the distal vs the proximal colon. Our study illustrates that TTE avoids such design-induced biases.
- 1 April 2025
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 195 (2) , 300-306
Misleading and avoidable: design-induced biases in observational studies evaluating cancer screening—the example of site-specific effectiveness of screening colonoscopy
Observational studies evaluating the effectiveness of cancer screening are often biased due to nonalignment at time zero, which can be avoided by target trial emulation (TTE). We aimed to illustrate this by evaluating site-specific effectiveness of screening colonoscopy regarding colorectal cancer (CRC) incidence. Based on a German health care database, we assessed the effect of screening colonoscopy vs no screening colonoscopy in preventing CRC in the distal and the proximal colon over 12 years of follow-up in 55-69-year-old persons. We compared four different study designs: cohort and case–control study, each with/without alignment at time zero. In both analyses with time zero-alignment, screening colonoscopy showed a rather similar effectiveness in reducing the incidence of distal and proximal CRC (cohort analysis: 32% (95% CI, 27%-37%) vs 28% (20%-35%); case–control analysis: 27% vs 33%). Both analyses without alignment suggested a difference by site: Incidence reduction regarding distal and proximal CRC, respectively, was 65% (61%-68%) vs 37% (31%-43%) in the cohort analysis and 77% (67%-84%) vs 46% (25%-61%) in the case–control analysis. Violations of basic design principles can substantially bias the results of observational studies. In our example, it falsely suggested a much stronger preventive effect of colonoscopy in the distal vs the proximal colon. Our study illustrates that TTE avoids such design-induced biases.
- Open Access
- 22 October 2024
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 176, 111571
13-Year colorectal cancer risk after lower-quality, higher-quality and no screening colonoscopy: a cohort study
- 22 October 2024
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 176, 111571
Open Access13-Year colorectal cancer risk after lower-quality, higher-quality and no screening colonoscopy: a cohort study
- Open Access
- 6 September 2024
- Published by Springer Nature in International Journal of Obesity
- Vol. 48 (11) , 1656-1663
Alcohol use disorders after bariatric surgery: a study using linked health claims and survey data
Background: Previous studies have repeatedly reported alcohol use disorders (AUDs) in patients after bariatric surgery (BS). This research field can benefit from studies combining health claims data with survey data. Methods: Based on a combined retrospective cohort and cross-sectional study, 2151 patients with BS identified in a large health claims database received a questionnaire, by which we assessed the presence of AUDs based on a validated instrument (AUDIT) as well as by ICD-10 codes from the health claims data. We described patients with vs. without AUDs regarding sex, time since surgery, satisfaction with weight loss and health care resource utilization (HCRU). Results: The majority of patients were female (80.7%) with a median time since surgery of 6 years (Interquartile range: 4–9 years). For the majority of patients, the bariatric intervention was either a RYGB-Bypass (50%) or sleeve gastrectomy (43%). Overall, 3% had at least one AUD diagnosis code in the claims data (men: 5.5%, women: 2.5%). Among men, 43.6% of diagnoses were coded after but not before the surgery (women: 52%). According to AUDIT (completed by 1496 patients), 9.4% of all patients showed at least hazardous/harmful alcohol consumption. Higher scores were associated with sex of the person, longer time since surgery, dissatisfaction with the weight loss and higher HCRU, with contradicting results regarding psychotherapeutic care. Conclusions: The proportion with AUDs in the study population gives rise to concern as alcohol consumption should be restricted after BS. The results suggest the necessity for close monitoring and post-surgical care.
- 6 September 2024
- Published by Springer Nature in International Journal of Obesity
- Vol. 48 (11) , 1656-1663
Open AccessAlcohol use disorders after bariatric surgery: a study using linked health claims and survey data
Background: Previous studies have repeatedly reported alcohol use disorders (AUDs) in patients after bariatric surgery (BS). This research field can benefit from studies combining health claims data with survey data. Methods: Based on a combined retrospective cohort and cross-sectional study, 2151 patients with BS identified in a large health claims database received a questionnaire, by which we assessed the presence of AUDs based on a validated instrument (AUDIT) as well as by ICD-10 codes from the health claims data. We described patients with vs. without AUDs regarding sex, time since surgery, satisfaction with weight loss and health care resource utilization (HCRU). Results: The majority of patients were female (80.7%) with a median time since surgery of 6 years (Interquartile range: 4–9 years). For the majority of patients, the bariatric intervention was either a RYGB-Bypass (50%) or sleeve gastrectomy (43%). Overall, 3% had at least one AUD diagnosis code in the claims data (men: 5.5%, women: 2.5%). Among men, 43.6% of diagnoses were coded after but not before the surgery (women: 52%). According to AUDIT (completed by 1496 patients), 9.4% of all patients showed at least hazardous/harmful alcohol consumption. Higher scores were associated with sex of the person, longer time since surgery, dissatisfaction with the weight loss and higher HCRU, with contradicting results regarding psychotherapeutic care. Conclusions: The proportion with AUDs in the study population gives rise to concern as alcohol consumption should be restricted after BS. The results suggest the necessity for close monitoring and post-surgical care.
- Open Access
Misleading and avoidable: design-induced biases in observational studies evaluating cancer screening -- the example of site-specific effectiveness of screening colonoscopy
Objective Observational studies evaluating the effectiveness of cancer screening are often biased due to an inadequate design where I) the assessment of eligibility, II) the assignment to screening vs. no screening and III) the start of follow-up are not aligned at time zero (baseline). Such flaws can entail misleading results but are avoidable by designing the study following the principle of target trial emulation (TTE). We aimed to illustrate this by addressing the research question whether screening colonoscopy is more effective in the distal vs. the proximal colon. Methods Based on a large German health care database (20% population coverage), we assessed the effect of screening colonoscopy in preventing distal and proximal CRC over 12 years of follow-up in 55–69-year-old persons at average CRC risk. We applied four different study designs and compared the results: cohort study with / without alignment at time zero, case control study with / without alignment at time zero. Results In both analyses with alignment at time zero, screening colonoscopy showed a similar effectiveness in reducing the incidence of distal and proximal CRC (cohort analysis: 32% (95% CI: 27% - 37%) vs. 28% (95% CI: 20% - 35%); case-control analysis: 27% vs. 33%). Both analyses without alignment at time zero suggested a difference in site-specific performance: Incidence reduction regarding distal and proximal CRC, respectively, was 65% (95% CI: 61% - 68%) vs. 37% (95% CI: 31% - 43%) in the cohort analysis and 77% (95% CI: 67% - 84%) vs. 46% (95% CI: 25% - 61%) in the case-control analysis. Conclusions Our study demonstrates that violations of basic design principles can substantially bias the results of observational studies on cancer screening. In our example, it falsely suggested a much stronger preventive effect of colonoscopy in the distal vs. the proximal colon. The difference disappeared when the same data were analyzed using a TTE approach, which is known to avoid such design-induced biases.
Open AccessMisleading and avoidable: design-induced biases in observational studies evaluating cancer screening -- the example of site-specific effectiveness of screening colonoscopy
Objective Observational studies evaluating the effectiveness of cancer screening are often biased due to an inadequate design where I) the assessment of eligibility, II) the assignment to screening vs. no screening and III) the start of follow-up are not aligned at time zero (baseline). Such flaws can entail misleading results but are avoidable by designing the study following the principle of target trial emulation (TTE). We aimed to illustrate this by addressing the research question whether screening colonoscopy is more effective in the distal vs. the proximal colon. Methods Based on a large German health care database (20% population coverage), we assessed the effect of screening colonoscopy in preventing distal and proximal CRC over 12 years of follow-up in 55–69-year-old persons at average CRC risk. We applied four different study designs and compared the results: cohort study with / without alignment at time zero, case control study with / without alignment at time zero. Results In both analyses with alignment at time zero, screening colonoscopy showed a similar effectiveness in reducing the incidence of distal and proximal CRC (cohort analysis: 32% (95% CI: 27% - 37%) vs. 28% (95% CI: 20% - 35%); case-control analysis: 27% vs. 33%). Both analyses without alignment at time zero suggested a difference in site-specific performance: Incidence reduction regarding distal and proximal CRC, respectively, was 65% (95% CI: 61% - 68%) vs. 37% (95% CI: 31% - 43%) in the cohort analysis and 77% (95% CI: 67% - 84%) vs. 46% (95% CI: 25% - 61%) in the case-control analysis. Conclusions Our study demonstrates that violations of basic design principles can substantially bias the results of observational studies on cancer screening. In our example, it falsely suggested a much stronger preventive effect of colonoscopy in the distal vs. the proximal colon. The difference disappeared when the same data were analyzed using a TTE approach, which is known to avoid such design-induced biases.
- 23 March 2023
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 130 (7) , 846-847
Authors’ reply
- 23 March 2023
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 130 (7) , 846-847
Authors’ reply
- Open Access
- 2 November 2022
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 14, 1293-1303
Effectiveness of Mammography Screening on Breast Cancer Mortality – A Study Protocol for Emulation of Target Trials Using German Health Claims Data
Background: The efficacy of mammography screening in reducing breast cancer mortality has been demonstrated in randomized trials. However, treatment options - and hence prognosis – for advanced tumor stages as well as mammography techniques have considerably improved since completion of these trials. Consequently, the effectiveness of mammography screening under current conditions is unclear and controversial. The German mammography screening program (MSP), an organized population-based screening program, was gradually introduced between 2005 and 2008 and achieved nation-wide coverage in 2009. Objective: We describe in detail a study protocol for investigating the effectiveness of the German MSP in reducing breast cancer mortality in women aged 50 to 69 years based on health claims data. Specifically, the proposed study aims at estimating per-protocol effects of several screening strategies on cumulative breast cancer mortality. The first analysis will be conducted once 10-year follow-up data are available. Methods and Analysis: We will use claims data from five statutory health insurance providers in Germany, covering approximately 37.6 million individuals. To estimate the effectiveness of the MSP, hypothetical target trials will be emulated across time, an approach that has been demonstrated to minimize design-related biases. Specifically, the primary contrast will be in terms of the cumulative breast cancer mortality comparing the screening strategies of “never screen” versus “regular screening as intended by the MSP”. Ethics and Dissemination: In Germany, the utilization of data from health insurances for scientific research is regulated by the Code of Social Law. All involved health insurance providers as well as the responsible authorities approved the use of the health claims data for this study. The Ethics Committee of the University of Bremen determined that studies based on claims data are exempt from institutional review. The findings of the proposed study will be published in peer-reviewed journals.
- 2 November 2022
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 14, 1293-1303
Open AccessEffectiveness of Mammography Screening on Breast Cancer Mortality – A Study Protocol for Emulation of Target Trials Using German Health Claims Data
Background: The efficacy of mammography screening in reducing breast cancer mortality has been demonstrated in randomized trials. However, treatment options - and hence prognosis – for advanced tumor stages as well as mammography techniques have considerably improved since completion of these trials. Consequently, the effectiveness of mammography screening under current conditions is unclear and controversial. The German mammography screening program (MSP), an organized population-based screening program, was gradually introduced between 2005 and 2008 and achieved nation-wide coverage in 2009. Objective: We describe in detail a study protocol for investigating the effectiveness of the German MSP in reducing breast cancer mortality in women aged 50 to 69 years based on health claims data. Specifically, the proposed study aims at estimating per-protocol effects of several screening strategies on cumulative breast cancer mortality. The first analysis will be conducted once 10-year follow-up data are available. Methods and Analysis: We will use claims data from five statutory health insurance providers in Germany, covering approximately 37.6 million individuals. To estimate the effectiveness of the MSP, hypothetical target trials will be emulated across time, an approach that has been demonstrated to minimize design-related biases. Specifically, the primary contrast will be in terms of the cumulative breast cancer mortality comparing the screening strategies of “never screen” versus “regular screening as intended by the MSP”. Ethics and Dissemination: In Germany, the utilization of data from health insurances for scientific research is regulated by the Code of Social Law. All involved health insurance providers as well as the responsible authorities approved the use of the health claims data for this study. The Ethics Committee of the University of Bremen determined that studies based on claims data are exempt from institutional review. The findings of the proposed study will be published in peer-reviewed journals.
- Open Access
- 7 October 2022
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 14, 1111-1122
Potential of Health Insurance Claims Data to Predict Fractures in Older Adults: A Prospective Cohort Study
Purpose: In older adults, fractures are associated with mortality, disability, loss of independence and high costs. Knowledge on their predictors can help to identify persons at high risk who may benefit from measures to prevent fractures. We aimed to assess the potential of German claims data to predict fractures in older adults. Patients and Methods: Using the German Pharmacoepidemiological Research Database (short GePaRD; claims data from ~20% of the German population), we included persons aged ≥ 65 years with at least one year of continuous insurance coverage and no fractures prior to January 1, 2017 (baseline). We randomly divided the study population into a training (80%) and a test sample (20%) and used logistic regression and random forest models to predict the risk of fractures within one year after baseline based on different combinations of potential predictors. Results: Among 2,997,872 persons (56% female), the incidence per 10,000 person years of any fracture in women increased from 133 in age group 65– 74 years (men: 71) to 583 in age group 85+ (men: 332). The maximum predictive performance as measured by the area under the curve (AUC) across models was 0.63 in men and 0.60 in women and was achieved by combining information on drugs and morbidities. AUCs were lowest in age group 85+. Conclusion: Our study showed that the performance of models using German claims data to predict the risk of fractures in older adults is moderate. Given that the models used data readily available to health insurance providers in Germany, it may still be worthwhile to explore the cost–benefit ratio of interventions aiming to reduce the risk of fractures based on such prediction models in certain risk groups.
- 7 October 2022
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 14, 1111-1122
Open AccessPotential of Health Insurance Claims Data to Predict Fractures in Older Adults: A Prospective Cohort Study
Purpose: In older adults, fractures are associated with mortality, disability, loss of independence and high costs. Knowledge on their predictors can help to identify persons at high risk who may benefit from measures to prevent fractures. We aimed to assess the potential of German claims data to predict fractures in older adults. Patients and Methods: Using the German Pharmacoepidemiological Research Database (short GePaRD; claims data from ~20% of the German population), we included persons aged ≥ 65 years with at least one year of continuous insurance coverage and no fractures prior to January 1, 2017 (baseline). We randomly divided the study population into a training (80%) and a test sample (20%) and used logistic regression and random forest models to predict the risk of fractures within one year after baseline based on different combinations of potential predictors. Results: Among 2,997,872 persons (56% female), the incidence per 10,000 person years of any fracture in women increased from 133 in age group 65– 74 years (men: 71) to 583 in age group 85+ (men: 332). The maximum predictive performance as measured by the area under the curve (AUC) across models was 0.63 in men and 0.60 in women and was achieved by combining information on drugs and morbidities. AUCs were lowest in age group 85+. Conclusion: Our study showed that the performance of models using German claims data to predict the risk of fractures in older adults is moderate. Given that the models used data readily available to health insurance providers in Germany, it may still be worthwhile to explore the cost–benefit ratio of interventions aiming to reduce the risk of fractures based on such prediction models in certain risk groups.
- Open Access
- 8 August 2022
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 129 (13) , 2107-2116
Use of combined oral contraceptives and risk of venous thromboembolism in young women: a nested case–control analysis using German claims data
Objective: To compare the risk of venous thromboembolism (VTE) among young women for nine combined oral contraceptives (COCs), including progestogens with an as yet unclear risk of VTE such as chlormadinone and nomegestrol, using COCs containing levonorgestrel with low ethinylestradiol (<50 μg) as a reference.Design: Case–control study nested in a cohort of new users of COCs.Setting: German claims data.Population: A total of 1166 cases of VTE matched to 11 660 controls nested in a cohort of 677 331 girls and young women aged 10–19 years with one or more COCs dispensed between 2005 and 2017 after a 1‐year period without any COCs.Methods: Confounder‐adjusted odds ratios (aORs) of VTE associated with current use of the respective COCs were calculated using conditional logistic regression.Main outcome measures: Venous thromboembolism (VTE), defined as a diagnosis of pulmonary embolism or deep vein thrombosis.Results: Compared with levonorgestrel with low ethinylestradiol (<50 μg), the risk of VTE was increased two‐fold for COCs containing dienogest (aOR 2.23, 95% CI 1.77–2.80), cyproterone (aOR 2.15, 95% CI 1.43–3.25), chlormadinone (aOR 2.06, 95% CI 1.58–2.68), desogestrel (aOR 1.93, 95% CI 1.44–2.61) and drospirenone (aOR 1.89, 95% CI 1.41–2.55), and increased five‐fold for gestodene (aOR 5.05, 95% CI 1.23–20.74). For norgestimate and nomegestrol, the point estimates suggest a two‐fold increased risk (aOR 1.90, 95% CI 0.62–5.81) and 40% increased risk (aOR 1.41, 95% CI 0.52–3.81), respectively.Conclusions: Our study confirms that levonorgestrel with low ethinylestradiol (<50 μg) is the COC associated with the lowest risk of VTE and suggests that for chlormadinone the risk of VTE is two times higher, and thus in the same range as for desogestrel and drospirenone.
- 8 August 2022
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 129 (13) , 2107-2116
Open AccessUse of combined oral contraceptives and risk of venous thromboembolism in young women: a nested case–control analysis using German claims data
Objective: To compare the risk of venous thromboembolism (VTE) among young women for nine combined oral contraceptives (COCs), including progestogens with an as yet unclear risk of VTE such as chlormadinone and nomegestrol, using COCs containing levonorgestrel with low ethinylestradiol (<50 μg) as a reference.Design: Case–control study nested in a cohort of new users of COCs.Setting: German claims data.Population: A total of 1166 cases of VTE matched to 11 660 controls nested in a cohort of 677 331 girls and young women aged 10–19 years with one or more COCs dispensed between 2005 and 2017 after a 1‐year period without any COCs.Methods: Confounder‐adjusted odds ratios (aORs) of VTE associated with current use of the respective COCs were calculated using conditional logistic regression.Main outcome measures: Venous thromboembolism (VTE), defined as a diagnosis of pulmonary embolism or deep vein thrombosis.Results: Compared with levonorgestrel with low ethinylestradiol (<50 μg), the risk of VTE was increased two‐fold for COCs containing dienogest (aOR 2.23, 95% CI 1.77–2.80), cyproterone (aOR 2.15, 95% CI 1.43–3.25), chlormadinone (aOR 2.06, 95% CI 1.58–2.68), desogestrel (aOR 1.93, 95% CI 1.44–2.61) and drospirenone (aOR 1.89, 95% CI 1.41–2.55), and increased five‐fold for gestodene (aOR 5.05, 95% CI 1.23–20.74). For norgestimate and nomegestrol, the point estimates suggest a two‐fold increased risk (aOR 1.90, 95% CI 0.62–5.81) and 40% increased risk (aOR 1.41, 95% CI 0.52–3.81), respectively.Conclusions: Our study confirms that levonorgestrel with low ethinylestradiol (<50 μg) is the COC associated with the lowest risk of VTE and suggests that for chlormadinone the risk of VTE is two times higher, and thus in the same range as for desogestrel and drospirenone.
- Open Access
- 29 July 2022
- Published by Springer Nature in Prävention und Gesundheitsförderung
- p. 1-8
Emulierung von „target trials“ mit Real-world-Daten
Zusammenfassung: Hintergrund: Die „real world data“ (RWD), z. B. Krankenkassendaten, bieten reichhaltige Informationen zu gesundheitsrelevanten Faktoren und können die Basis für Studien zur Arzneimittelsicherheit, Wirksamkeit medizinischer Interventionen u. v. m. darstellen. Ein besonderer Vorteil ist die je nach Datenquelle größere Verallgemeinerbarkeit, wenn z. B. Informationen zu bestimmten Subgruppen der Population vorliegen und ein Volunteer-Bias ausgeschlossen werden kann. Gerade in Fällen, in denen randomisierte kontrollierte Studien („randomized controlled trials“, RCT) nicht durchgeführt werden können, sind Beobachtungsstudien basierend auf RWD eine wichtige Informationsquelle. Die valide Analyse von RWD stellt allerdings einige Herausforderung dar, wobei insbesondere mögliche Verzerrungen, die durch ein sorgfältiges Studiendesign vermeidbar wären, Beachtung finden sollen. Hier setzt das Prinzip der Target-trial-Emulierung (TTE) an. Ziel der Arbeit: In diesem Artikel soll aufgezeigt werden, wie die TTE den Herausforderungen bei der Analyse von RWD begegnet. Material und Methoden: Die TTE wird allgemein verständlich vorgestellt. Prinzipien, Vorteile, Annahmen und spezifische statistische Aspekte werden anhand relevanter Literatur und praktischer Beispiele erläutert. Ergebnisse: Damit die Analyse von RWD valide, kausal interpretierbare Ergebnisse liefern kann, müssen einige Bedingungen erfüllt sein. Neben einem ausreichenden Informationsgehalt der Daten sind auch eine klare Fragestellung und ein geeignetes Studiendesign, das u. a. Selektionseffekte vermeidet, von zentraler Bedeutung. Das Target-trial-Prinzip besteht darin, dass zunächst das Auswertungskonzept für einen RCT erarbeitet wird, welches in einem zweiten Schritt mit Beobachtungsdaten „emuliert“ wird. Somit liefert die TTE quasi eine Anleitung, um die Fragestellung zu definieren und ein geeignetes Studiendesign zu entwerfen. TTE kann mit unterschiedlichen statistischen Methoden kombiniert werden, wobei statistische Effizienz durch sequenzielle Trials und das sog. Klonen gewonnen werden kann. Schlussfolgerung: Die TTE ist ein allgemeines und übergreifendes Prinzip, das zentralen Herausforderungen bei der Analyse von Beobachtungsdaten, also auch RWD, systematisch begegnet.
- 29 July 2022
- Published by Springer Nature in Prävention und Gesundheitsförderung
- p. 1-8
Open AccessEmulierung von „target trials“ mit Real-world-Daten
Zusammenfassung: Hintergrund: Die „real world data“ (RWD), z. B. Krankenkassendaten, bieten reichhaltige Informationen zu gesundheitsrelevanten Faktoren und können die Basis für Studien zur Arzneimittelsicherheit, Wirksamkeit medizinischer Interventionen u. v. m. darstellen. Ein besonderer Vorteil ist die je nach Datenquelle größere Verallgemeinerbarkeit, wenn z. B. Informationen zu bestimmten Subgruppen der Population vorliegen und ein Volunteer-Bias ausgeschlossen werden kann. Gerade in Fällen, in denen randomisierte kontrollierte Studien („randomized controlled trials“, RCT) nicht durchgeführt werden können, sind Beobachtungsstudien basierend auf RWD eine wichtige Informationsquelle. Die valide Analyse von RWD stellt allerdings einige Herausforderung dar, wobei insbesondere mögliche Verzerrungen, die durch ein sorgfältiges Studiendesign vermeidbar wären, Beachtung finden sollen. Hier setzt das Prinzip der Target-trial-Emulierung (TTE) an. Ziel der Arbeit: In diesem Artikel soll aufgezeigt werden, wie die TTE den Herausforderungen bei der Analyse von RWD begegnet. Material und Methoden: Die TTE wird allgemein verständlich vorgestellt. Prinzipien, Vorteile, Annahmen und spezifische statistische Aspekte werden anhand relevanter Literatur und praktischer Beispiele erläutert. Ergebnisse: Damit die Analyse von RWD valide, kausal interpretierbare Ergebnisse liefern kann, müssen einige Bedingungen erfüllt sein. Neben einem ausreichenden Informationsgehalt der Daten sind auch eine klare Fragestellung und ein geeignetes Studiendesign, das u. a. Selektionseffekte vermeidet, von zentraler Bedeutung. Das Target-trial-Prinzip besteht darin, dass zunächst das Auswertungskonzept für einen RCT erarbeitet wird, welches in einem zweiten Schritt mit Beobachtungsdaten „emuliert“ wird. Somit liefert die TTE quasi eine Anleitung, um die Fragestellung zu definieren und ein geeignetes Studiendesign zu entwerfen. TTE kann mit unterschiedlichen statistischen Methoden kombiniert werden, wobei statistische Effizienz durch sequenzielle Trials und das sog. Klonen gewonnen werden kann. Schlussfolgerung: Die TTE ist ein allgemeines und übergreifendes Prinzip, das zentralen Herausforderungen bei der Analyse von Beobachtungsdaten, also auch RWD, systematisch begegnet.
- Open Access
- 6 June 2022
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 149, 118-126
Screening colonoscopy similarly prevented distal and proximal colorectal cancer: a prospective study among 55–69-year-olds
- 6 June 2022
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 149, 118-126
Open AccessScreening colonoscopy similarly prevented distal and proximal colorectal cancer: a prospective study among 55–69-year-olds